Provided by Tiger Trade Technology Pte. Ltd.

Celldex Therapeutics

31.65
-0.5300-1.65%
Post-market: 32.000.3500+1.11%19:38 EDT
Volume:2.41M
Turnover:76.17M
Market Cap:2.48B
PE:-7.29
High:32.54
Open:32.26
Low:30.98
Close:32.18
52wk High:45.14
52wk Low:22.10
Shares:78.49M
Float Shares:73.02M
Volume Ratio:1.22
T/O Rate:3.29%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.3401
EPS(LYR):-3.9000
ROE:-43.88%
ROA:-27.62%
PB:3.48
PE(LYR):-8.12

Loading ...

Celldex adverse event concerns overblown, says H.C. Wainwright

TIPRANKS
·
Yesterday

Celldex Therapeutics Price Target Maintained with a $64.00/Share by HC Wainwright & Co.

Dow Jones
·
Yesterday

Analysts Offer Insights on Healthcare Companies: Celldex (CLDX), Nanobiotix (NBTX) and Senseonics Holdings (SENS)

TIPRANKS
·
Sep 28

Belgium's Celyad H1 Net Loss Narrows on Lower Expenses

Reuters
·
Sep 24

Canaccord Genuity Sticks to Their Buy Rating for Celldex (CLDX)

TIPRANKS
·
Sep 23

Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Celldex (CLDX) and Inventiva (IVA)

TIPRANKS
·
Sep 23

Wells Fargo Keeps Their Buy Rating on Celldex (CLDX)

TIPRANKS
·
Sep 23

US Research Roundup- Allstate, Autozone, Vertex Pharmaceuticals

Reuters
·
Sep 23

Top Midday Decliners

MT Newswires Live
·
Sep 23

Celldex Therapeutics is Maintained at Overweight by Cantor Fitzgerald

Dow Jones
·
Sep 22

U.S. Stocks on the MOVE-Greenland Mines, GameStop, Shopify

Reuters
·
Sep 22

Celldex price target raised to $64 from $42 at H.C. Wainwright

TIPRANKS
·
Sep 22

Celldex Shares Slip as Safety Concerns Cloud Skin Drug Trial Win

Reuters
·
Sep 22

Celldex Falls After Two Probable Anaphylaxis Cases in Trials

Reuters
·
Sep 22

Celldex falls -5.1%

TIPRANKS
·
Sep 22

Celldex Therapeutics Shares Fall 1.9% After Data from Late-Stage Trials of Its Skin Disease Drug

THOMSON REUTERS
·
Sep 22

Celldex Therapeutics Shares Reverse Course; Last Down 19.2% Premarket

THOMSON REUTERS
·
Sep 22

Celldex Therapeutics Shares up 21% Premarket After Co's Skin Condition Drug Barzolvolimab Meets Primary and All Key Secondary Endpoints

THOMSON REUTERS
·
Sep 22

Celldex’s barzolvolimab meets endpoints in Phase 3 urticaria trial

TIPRANKS
·
Sep 22

Celldex Says Barzolvolimab Meets Primary Endpoint in Phase 3 Embarq-CSU Studies for Chronic Spontaneous Urticaria

Reuters
·
Sep 22